|
审核状态: Project audit state: |
通过审核 Successful |
|
注册号: Registration number: |
ChiCTR2300076879 |
|
最近更新日期: Date of Last Refreshed on: |
2023-10-23 14:31:21 |
|
注册时间: Date of Registration: |
2023-10-23 00:00:00 |
|
注册号状态: |
预注册 |
|
Registration Status: |
Prospective registration |
|
注册题目: |
妊娠合并肺动脉高压患者回顾性调查研究 |
|
Public title: |
Retrospective investigation of pregnant women with pulmonary hypertension |
|
注册题目简写: |
|
|
English Acronym: |
|
|
研究课题的正式科学名称: |
妊娠合并肺动脉高压患者回顾性调查研究 |
|
Scientific title: |
Retrospective investigation of pregnant women with pulmonary hypertension |
|
研究课题代号(代码): Study subject ID: |
|
|
在二级注册机构或其它机构的注册号: The registration number of the Partner Registry or other register: |
|
申请注册联系人: |
康焱茗 |
研究负责人: |
江晓琴 |
|
Applicant: |
Yanming Kang |
Study leader: |
Xiaoqin Jiang |
|
申请注册联系人电话: Applicant telephone: |
+86 158 8455 7879 |
研究负责人电话:
Study leader's |
+86 138 0822 4829 |
|
申请注册联系人传真 : Applicant Fax: |
研究负责人传真: Study leader's fax: |
||
|
申请注册联系人电子邮件: Applicant E-mail: |
kyanming@scu.edu.cn |
研究负责人电子邮件: Study leader's E-mail: |
jxq1598862657@163.com |
|
申请单位网址(自愿提供): Applicant website(voluntary supply): |
四川大学华西第二医院 |
研究负责人网址(自愿提供): Study leader's website(voluntary supply): |
四川大学华西第二医院 |
|
申请注册联系人通讯地址: |
四川省成都市武侯区人民南路三段20号 |
研究负责人通讯地址: |
四川省成都市武侯区人民南路三段20号 |
|
Applicant address: |
20, Section 3, Renmin South Road, Wuhou District, Chengdu City, Sichuan Province |
Study leader's address: |
20, Section 3, Renmin South Road, Wuhou District, Chengdu City, Sichuan Province |
|
申请注册联系人邮政编码: Applicant postcode: |
研究负责人邮政编码: Study leader's postcode: |
||
|
申请人所在单位: |
四川大学华西第二医院 |
||
|
Applicant's institution: |
West China Second Hospital, Sichuan University |
||
|
研究负责人所在单位: |
四川大学华西第二医院 |
||
|
Affiliation of the Leader: |
West China Second Hospital, Sichuan University |
||
|
是否获伦理委员会批准: |
是 |
||
|
Approved by ethic committee: |
Yes |
||
|
伦理委员会批件文号: Approved No. of ethic committee: |
医学科研2023伦审批第(214)号 |
伦理委员会批件附件: Approved file of Ethical Committee: |
查看附件View |
|
批准本研究的伦理委员会名称: |
四川大学华西第二医院医学伦理委员会 |
||
|
Name of the ethic committee: |
Medical Ethics Committee of West China Second Hospital, Sichuan University |
||
|
伦理委员会批准日期: Date of approved by ethic committee: |
2023-08-14 00:00:00 | ||
|
伦理委员会联系人: |
马驰 |
||
|
Contact Name of the ethic committee: |
Chi Ma |
||
|
伦理委员会联系地址: |
四川大学华西第二医院 |
||
|
Contact Address of the ethic committee: |
West China Second Hospital, Sichuan University |
||
|
伦理委员会联系人电话: Contact phone of the ethic committee: |
+86 28 8857 0104 |
伦理委员会联系人邮箱: Contact email of the ethic committee: |
|
|
研究实施负责(组长)单位: |
四川大学华西第二医院 |
||||||||||||||||||||||
|
Primary sponsor: |
West China Second Hospital, Sichuan University |
||||||||||||||||||||||
|
研究实施负责(组长)单位地址: |
四川省成都市武侯区人民南路三段20号 |
||||||||||||||||||||||
|
Primary sponsor's address: |
20, Section 3, Renmin South Road, Wuhou District, Chengdu City, Sichuan Province |
||||||||||||||||||||||
|
试验主办单位(项目批准或申办者): Secondary sponsor: |
|
||||||||||||||||||||||
|
经费或物资来源: |
个人 |
||||||||||||||||||||||
|
Source(s) of funding: |
personal |
||||||||||||||||||||||
|
研究疾病: |
肺动脉高压 |
||||||||||||||||||||||
|
Target disease: |
Pulmonary hypertension |
||||||||||||||||||||||
|
研究疾病代码: |
|
||||||||||||||||||||||
|
Target disease code: |
|
||||||||||||||||||||||
|
研究类型: |
观察性研究 |
||||||||||||||||||||||
|
Study type: |
Observational study |
||||||||||||||||||||||
|
研究所处阶段: |
回顾性研究 | ||||||||||||||||||||||
|
Study phase: |
Retrospective study |
||||||||||||||||||||||
|
研究设计: |
连续入组 |
||||||||||||||||||||||
|
Study design: |
Sequential |
||||||||||||||||||||||
|
研究目的: |
分析各类妊娠合并肺动脉高压患者临床特点及并发症;预测妊娠合并肺动脉高压患者心血管并发症相关风险因素 |
||||||||||||||||||||||
|
Objectives of Study: |
To analyze the clinical characteristics and complications of all kinds of pregnancy patients with pulmonary hypertension. To predict the risk factors related to cardiovascular complications in pregnancy patients with pulmonary hypertension |
||||||||||||||||||||||
|
药物成份或治疗方案详述: |
|
||||||||||||||||||||||
|
Description for medicine or protocol of treatment in detail: |
|
||||||||||||||||||||||
|
纳入标准: |
2009 年-2023 年 2 月期间,在四川大学华西第二医院就诊的妊娠合并肺动脉高压患者 1、在我院接受超声心动图监测的患者; 2、符合超声心动图肺动脉高压标准(PAP >35 mmHg)的患者; 3、病历完整的患者。 |
||||||||||||||||||||||
|
Inclusion criteria |
Pregnant patients with pulmonary hypertension who were treated at West China Second Hospital of Sichuan University from 2009 to February 2023: 1. Patients who received UCG monitoring in our hospital; 2. Patients who conform to echocardiographic criteria of pulmonary hypertension(PAP >35 mmHg); 3. Patients with complete medical record. |
||||||||||||||||||||||
|
排除标准: |
病历资料不完整患者 |
||||||||||||||||||||||
|
Exclusion criteria: |
Pregnant women with pulmonary hypertension with incomplete clinical data were excluded |
||||||||||||||||||||||
|
研究实施时间: Study execute time: |
从 From 2023-10-25 00:00:00至 To 2023-12-31 00:00:00 |
征募观察对象时间: Recruiting time: |
从 From 2023-10-25 00:00:00 至 To 2023-12-31 00:00:00 |
|
干预措施: Interventions: |
|
|
研究实施地点: Countries of recruitment and research settings: |
|
||||||||||||||||||||||||||||
|
测量指标: Outcomes: |
|
|
采集人体标本:
Collecting sample(s)
|
|
|
征募研究对象情况: Recruiting status: |
尚未开始 Not yet recruiting |
年龄范围: Participant age: |
|
||||||
|
性别: |
女性 |
Gender: |
Female |
||||||
|
随机方法(请说明由何人用什么方法产生随机序列): |
不适用 |
||||||||
|
Randomization Procedure (please state who generates the random number sequence and by what method): |
N/A |
||||||||
|
是否公开试验完成后的统计结果: Calculated Results after the Study Completed public access: |
公开/Public |
|
盲法: |
不适用 |
|
Blinding: |
N/A |
|
试验完成后的统计结果(上传文件): |
|
|
Calculated Results after
|
|
|
是否共享原始数据: IPD sharing |
是Yes |
|
共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址): |
http://www.medresman.org.cn/login.aspx |
|
The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url): |
http://www.medresman.org.cn/login.aspx |
|
数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC: |
数据记录采用纸质和电子版病例记录表,数据管理使用ResMan临床试验公共管理平台 |
|
Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture: |
Paper and electronic case record forms were used for data recording, and the ResMan clinical trial public management platform was used for data management |
|
数据与安全监察委员会: Data and Safety Monitoring Committee: |
暂未确定/Not yet |